State of Wisconsin Investment Board raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 10.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,462,840 shares of the company’s stock after buying an additional 227,830 shares during the quarter. State of Wisconsin Investment Board owned 0.24% of Teva Pharmaceutical Industries Limited worth $43,346,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TEVA. American International Group Inc. bought a new stake in shares of Teva Pharmaceutical Industries Limited in the 1st quarter worth approximately $523,000. Teachers Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries Limited by 6.1% in the 1st quarter. Teachers Advisors LLC now owns 642,314 shares of the company’s stock worth $20,612,000 after acquiring an additional 36,900 shares during the period. Bank of Nova Scotia bought a new stake in shares of Teva Pharmaceutical Industries Limited in the 1st quarter worth approximately $391,000. Xact Kapitalforvaltning AB bought a new stake in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter worth approximately $269,000. Finally, Hexavest Inc. lifted its position in shares of Teva Pharmaceutical Industries Limited by 0.4% in the 2nd quarter. Hexavest Inc. now owns 322,232 shares of the company’s stock worth $10,705,000 after acquiring an additional 1,198 shares during the period. 56.45% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at $11.47 on Wednesday. The company has a market capitalization of $12,608.56, a price-to-earnings ratio of 2.87 and a beta of 0.52. Teva Pharmaceutical Industries Limited has a 52 week low of $10.85 and a 52 week high of $42.90. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.085 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 annualized dividend and a dividend yield of 2.97%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -15.80%.

COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Shares Bought by State of Wisconsin Investment Board” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-shares-bought-by-state-of-wisconsin-investment-board/1687961.html.

TEVA has been the subject of a number of research reports. Credit Suisse Group set a $39.00 price objective on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Vetr upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective for the company in a research report on Monday, July 24th. Deutsche Bank AG reiterated a “buy” rating and issued a $28.00 price objective (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. BTIG Research upgraded Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Monday, September 11th. Finally, Gabelli reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, September 13th. Six investment analysts have rated the stock with a sell rating, eighteen have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries Limited presently has a consensus rating of “Hold” and an average price target of $23.26.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.